New Horizons in the Management of Metastatic Pancreatic Cancer

Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC.

This activity is supported by an independent education grant from Merrimack Pharmaceuticals.

Scroll to the Bottom of this Information to Begin this Course

Release date: February 15, 2017

Valid through: August 15, 2017

Specialty: Oncology

Topic: Pancreatic Cancer

Media: Internet

Estimated Time to Complete Activity: 60 minutes

Target Audience

This activity is intended for medical oncologists, gastroenterologists, and other health care professionals (primary care physicians, physicians-in-training, oncology nurses, nurse practitioners, pharmacists, physician assistants, etc.) involved or interested in the management of patients with pancreatic cancer.

Learning Objectives

At the conclusion of this activity, participants will be able to:

  • Examine the safety and efficacy data of emerging and available treatment options for patients with metastatic pancreatic cancer
  • Evaluate and select optimal treatment algorithms for patients with metastatic pancreatic cancer

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credits

All other healthcare professionals completing this course will be issued a statement of participation.

Faculty

Eileen M. O’Reilly, MD

Professor of Medicine
Weill Cornell Medical College
Associate Director, Clinical Research
David M. Rubenstein Center for Pancreatic Cancer
Attending Physician, Member
Memorial Sloan Kettering Cancer Center

Andrea Wang-Gillam, MD, PhD

Associate Professor, Department of Medicine
Director of GI Oncology Program
Washington University School of Medicine

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Live Activity
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Enduring Material
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Presenters:

Eileen M. O’Reilly, MD
  • Consulting Fees: Aduro Biotech, Agios, Array, Aslan, Astellas Pharma US, Bayer, Blueprint, Boston Scientific, BMS, CASI, Celgene, Celsion, Delcath, Eisai, EMD Serono, Gilead, Halozyme, Integragen, Ipsen, Jansen, Merck, Merrimack, Momenta, New B Innovation, NewLink Genetics, Onxeo, Opsona, Pfizer, Roche, Sanofi-Aventis, Servier, Silenseed, Sillajen, Sirtex, Vaxxim, Vicus Therapeutics, Westhaven
  • Contracted Research: Amgen, Astra Zeneca, Bayer, BMS, CASI, Celgene, Chugai, Exelixis, Genentech Inc., Incyte, Lilly, Mabvax, Medimmune, Momenta, Myriad Genetics, OncoMed PharmaceuticalsPolaris Pharmaceuticals, Roche, Vicus Therapeutics
Andrea Wang-Gillam, MD, PhD
  • Consulting Fees: Merrimack, Pfizer, Newlink Genetics

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Hamsa Jaganathan, PhD, Medical Director, PlatformQ Health Education, LLC: None

The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose

The following PlatformQ Health Education, LLC planner, Elizabeth del Nido, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Instructions for Participation and Credit

There are no fees to participate in this activity. To participate in the activity, go to www.omedlive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.

Hardware and Software Requirements

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:

Please contact the Postgraduate Institute for Medicine at www.pimed.com.

Technical Support:

For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com